Gerald S. Falchook, MD, MS
Director, Drug Development, Sarah Cannon Research Institute at HealthONE
Dr. Falchook is the director of drug development for Sarah Cannon Research Institute at HealthONE, a clinical trials program which opened in 2014 in Denver for patients with advanced cancer. Previously, Dr. Falchook was a faculty member at U.T. MD Anderson Cancer Center for six years, developing investigator-initiated clinical trials, as well as collaborating with biotech industry partners to bring promising new drugs to cancer patients.
Dr. Falchook has been the principal investigator or co-investigator of more than 200 clinical studies, including first-in-human studies and regimens that have received FDA approval. His research has been published extensively in peer-reviewed journals, including in the New England Journal of Medicine and The Lancet.